A. Thomas McLellan, Ph.D was the principal developer of the Addiction Severity Index (ASI) and the Treatment Services Review (TSR), measurement instruments that characterize the multiple dimensions of substance abusing patients and treatments. These tools have been translated into over 20 languages and are the most widely used instruments of their kind in the world. They were created with the view that substance abuse and addiction could not be adequately understood and addiction treatments could not be adequately delivered if there were no relevant real-world methods to gauge them. The ASI and TSR have helped to revolutionize the delivery of treatment and helped researchers and clinicians gain more insight into the efficacy of treatment.

Dr. McLellan's work has also promoted better understanding of the factors that lead to treatment success, and has fostered greater understanding of addiction as a chronic illness, reduced its stigma, and provided means for earlier identification and prevention.

In 1992, Dr. McLellan founded the Treatment Research Institute as an independent, not-for-profit institute dedicated to taking scientific methods and findings from controlled studies and using them in real-world studies to give science an opportunity to influence clinical practice and public policy. Dr. McLellan has published more than 400 articles and chapters on addiction research and serves as editor in chief of the Journal of Substance Abuse Treatment. He serves on the editorial boards and as a reviewer of numerous medical and scientific journals.

Dr. Logan is a native of Glasgow, Scotland and holds a B.Sc (hons) and Ph.D. degrees from the University of Glasgow. Board Certified by the American Board of Forensic Toxicology and a member of their Board of Directors, he is the author of more than 70 peer-reviewed publications in the field of forensic toxicology and drug analysis. Dr. Logan has made drug-impaired driving a focus of his research activities since 1994, with more than 25 publications on this topic, and regularly testifies as an expert in drug impaired driving cases. Dr. Logan serves on many professional and public boards and committees, including the International Association of Forensic Toxicologists from which he received in 2003 the Mid-Career Achievement Award for Excellence in Forensic Toxicology for his work in postmortem and impaired driving toxicology. Dr. Logan lives in Bellevue, Washington, with his wife, Linda, and their three children.

The fifth McGovern Award for Leadership in Drug Abuse Prevention, and first of 2005, went to Charles G. Curie, M.A., A.C.S.W., Administrator of SAMHSA. Mr. Curie was nominated by President George W. Bush and confirmed by the U.S. Senate in the fall of 2001 as Administrator of the Substance Abuse and Mental Health Services Administration. SAMHSA is the leading federal agency working to improve the quality and availability of substance abuse prevention and treatment as well as mental health services in the United States.

Charles Curie has more than 25 years of impressive professional experience in the areas of mental health and substance abuse. His core commitment to ensuring that people with addictive and mental disorders have the opportunity to achieve full participation in American society has earned him national recognition. Mr. Curie has provided SAMHSA with outstanding and effective leadership in dealing with mental illness, alcoholism and drug abuse by creating new linkages among programs dealing with these serious human problems at the national, state and local levels.

CADCA Chairman & CEO General Arthur T. Dean, IBH President Robert L. DuPont, M.D. and SAMHSA Administrator Charles G. Curie.

ONDCP Special Assistant to the Director David Murray and Robert L. DuPont.

David G. Evans and Lisa Brady, IBH's McGovern Award recipients for Leadership in Substance Abuse Prevention, with IBH President Robert L. DuPont, MD after the June 27, 2003 award luncheon.

David Evans is the Executive Director of the Drug Free Schools Coalition and is a practicing attorney. He is nationally known for his expertise in the area of drug testing law and developing legally defensible and effective anti-drug programs and policies. Mr. Evans was chairperson of the Drug Testing Task Force of the Hunterdon Central Regional High School that developed the student drug testing program highlighted by ONDCP in their recent booklet What You Need to Know About Drug Testing in Schools [pdf version]. A powerful advocate for substance abuse prevention, Mr. Evans has written extensively on the topic. His books include Kids, Drugs and the Law and several on designing effective drug testing programs. Lisa Brady is the principal of Hunterdon Central Regional High School in Flemington, New Jersey, and has been involved in student drug testing since 1997. She is an original member of the school's Random Drug Testing Task Force and helped develop one of the first student drug testing policies in the country. The school program has been identified nationally as a model program and is featured in the ONDCP publication, What You Should Know About Drug Testing In Schools [pdf version]. Ms. Brady is the President of the Drug Free Schools Coalition and works as a consultant with school districts across the country to help them design and implement student drug testing programs. Brady is also the author of a number of articles on this type of program.

J. Michael Walsh, Ph.D., has been a national and international leader in drug abuse prevention for more than two decades. He was instrumental in the development of the workplace drug prevention efforts begun in the 1980s. In recent years, Dr. Walsh has taken the lead in reducing driving under the influence of drugs (DUI-D).

J. Michael Walsh, Ph.D., discusses recent research into drug-imaired driving.

Carl Selavka, Ph.D., explains current drug testing technologies. Following Dr. Walsh's presentation of his recent research, forensic toxicologist Carl Selavka, Ph.D., discussed relevant drug testing technology.

John Walters has shown remarkable leadership in the nation's efforts to curb illegal drug use in a wide range of distinguished roles over more than a decade. He has refocused the Office of National Drug Control Policy (ONDCP) on an ambitious goal of reducing the use of illegal drugs by 10% over the next two years and by 25% in the next five years. Mr. Walters has provided important leadership in reducing workplace drug abuse, a critical element in the war on illegal drug use. Having worked extensively with both labor and management, he is uniquely positioned to build accord within these often-contentious relationships and encourage progress toward safer, healthier work environments.

---

---

---

The John P. McGovern Lecture Series on Leadership in Drug Abuse Prevention

The McGovern Lecture was created to promote innovations in drug abuse prevention by identifying and supporting ideas that can guide effective actions throughout the world.

The Lecture is sponsored by the Institute for Behavior and Health, Inc., with generous support from the John P. McGovern Foundation.

---

2004 McGovern Lecture Series Begins with Focus on Drugged Driving Legislation

May 19, 2004

Michael McEleney
Legislative Director
Office of Representative Rob Porter (R-NV)

J. Michael Walsh, Ph.D.
President
The Walsh Group

Washington, DC

On May 19, 2004, the Institute for Behavior and Health, Inc. launched a new series of McGovern Lectures with a discussion of new progress against driving under the influence of drugs (DUID).

The luncheon meeting included a presentation from J. Michael Walsh, Ph.D., on DUID programs currently underway in Europe and Australia. An international expert on drug-impaired driving, Dr. Walsh convened the recent International Symposium on Drug-Impaired Driving (Developing Global Strategies for Identifying, Prosecuting, and Treating Drug-Impaired Drivers) and discussed highlights from the presented research. Dr. Walsh also reviewed his findings from the 2003 study of seriously injured drivers admitted to the University of Maryland's Shock Trauma Center. Results showed that significantly more of these drivers in serious accidents were impaired by illegal drug use than were impaired by the use of alcohol.

Following Dr. Walsh's presentation, Mike McEleney, Legislative Director for Congressman Jon Porter (R-NV), updated the group on current drug-impaired driving legislation in Congress. Representatives Porter and Rob Portman (R-OH) co-authored federal DUID legislation passed by the House of Representatives in April 2004. Discussing the House legislation and prospects for similar action by the Senate, Mr. McEleney called for greater public awareness and involvement in this issue.

McGovern Lecturer Mike McEleney, Legislative Director for Representative Rob Porter (R-NV), discusses federal DUID legislation at the May 19 luncheon.

Maj. General Arthur Dean (Ret.), Chairman and CEO of the Community Anti-Drug Coalitions of America (CADCA), urged outreach to community coalitions and grassroots organizations. Other special guests included representatives of the American Automobile Association Foundation, NHTSA, SAMHSA, Center for Alcohol and Drug Research and Education (CADRE), the Drug and Alcohol Testing Industry Association (DATIA), Washington/Baltimore HIDTA, and the Maryland House of Delegates.

Click here to view the May 19, 2004 DUID Press Release.

---

September 15, 2003

David Brill, MD
President and CEO
DrugRisk Solutions, Inc.

Tom Eden, Esq.
National Advisor on Student Drug Testing

Washington, DC

IBH presented the John P. McGovern Lecture on Leadership in Substance Abuse Prevention on September 15, 2003. David Brill, MD, MA, MPH, and Tom Eden, Esq., presented the Lecture as part of the Bensinger DuPont & Associates 13th Annual Conference on Workplace Prevention. The conference took place at the J.W. Marriott Hotel at 1331 Pennsylvania Avenue, NW, in Washington, DC.

Dr. Brill discussed the potential policy applications of a new onsite hair drug test developed by DrugRisk Solutions, LLC. This newly available screening technology will strengthen testing options for substance abuse prevention, detection and treatment. Thomas Eden, Esq. spoke on the optimal integration of this powerful new technology into existing law, policy and industry models.

---

---

---

Driving Under the Influence of Drugs (DUID) Working Group

May 28, 2003 Meeting

Sam Niedebala, PhD
Executive Vice President and Chief Science Officer
OraSure Technologies, Inc.

J. Michael Walsh, PhD
President
The Walsh Group

Washington, DC

IBH gathered a diverse group for the second in a series of meetings to discuss driving under the influence of drugs (DUI-D). This time, the focus was on the technology currently available for roadside testing for illegal drugs. The goal for the discussion was to find answers to the question: "Is Oral Fluids Testing Ready for Prime Time at the Roadside?" R. Sam Niedebala, PhD, Executive Vice President, Chief Science Officer and a founder of OraSure Technologies, Inc., updated the group on recent technological developments and testing innovations (click here to read a summary of Dr. Neidebala's presentation). J. Michael Walsh, President, The Walsh Group, discussed DUI-D studies in Europe. In addition to sensitizing some of the key stakeholders to this virtually ignored problem, the discussion showcased the need for demonstration projects as the first phase in developing workable, affordable and effective programs. These models should be developed at the state and local levels using a variety of approaches and participants.

Sam Niedebala, PhD, Executive Vice President and Chief Science Officer for OraSure Technologies, Inc., shared results from demonstration projects using oral fluids testing.

J. Michael Walsh, PhD, explained the European research into roadside testing and the implications for such initiatives in the United States.

Institute For Behavior and Health 6191 Executive Boulevard Rockville, MD 20852

phone (301) 231-9010 fax (301) 770-6876 contactus@ibhinc.org